ClinicalTrials.gg
Not yet recruitingNCT07316972CEST-BESTUpdated Oct 1, 2026

CEST-based Biomarkers to Delineate the Epileptogenic Zone

An interventional study of CEST sequence on a 7-Tesla MRI in Epilepsy (Treatment Refractory), sponsored by Fondation Ophtalmologique Adolphe de Rothschild. Not yet recruiting. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Fondation Ophtalmologique Adolphe de Rothschild · Not applicable, Interventional, and Other

How we know

Updated Oct 1, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Epilepsy by Fondation Ophtalmologique Adolphe de Rothschild — 7 open to participants now, 7 under way, none of them phase 3. Epilepsy · Fondation Ophtalmologique Adolphe de Rothschild.

Started
2027
the only one that year
No phase
3 of 10
2 open now
Registered
10th of 10
by date

Among the 10 studies in Epilepsy by Fondation Ophtalmologique Adolphe de Rothschild, this one is the only one that started in 2027, is one of 3 with no phase, and was the 10th registered.

Epilepsy

1,850 studies on the registry are indexed under Epilepsy; 418 are open to participants now.

Browse Epilepsy studies →

Open to participants now

7 of the 10 studies in Epilepsy by Fondation Ophtalmologique Adolphe de Rothschild are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 284 Epilepsy studies recruiting now, 113 (40%) set no upper age limit and 148 (52%) stop at 75 or younger; 138 take children under 18; 54 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Epilepsy by Fondation Ophtalmologique Adolphe de Rothschild, or all of them as a file.
02

Study summary

Epilepsy is a common neurological disorder with an incidence of 1%. Although many anti-seizure medications are available, about 30% of patients are resistant to drug treatments. Epilepsy surgery is an effective treatment for some of these patients. It involves removing the brain region responsible for generating seizures, called the epileptogenic zone (EZ).

A pre-surgical evaluation is performed to locate and delineate the region where seizures originate (the seizure onset zone [SOZ]) and to confirm that this zone is unique and accessible for surgery-that is, that the potential benefits outweigh the risks of functional deficits resulting from its removal. The lesion itself is identified and characterized through post-operative histological examination and, in some cases, based on MRI criteria.

During pre-surgical evaluation, in cases where no lesion is visible on MRI or when surface EEG suggests that a large or multiple epileptic networks may be involved, stereo-electroencephalography (SEEG) is the method of choice to delineate the area for resection. However, SEEG has limitations: it is invasive and records from a restricted brain volume.

Despite advances in neuroimaging techniques, the localization of the epileptogenic zone and mapping of functional brain alterations still need improvement beyond what morphological MRI anomalies can reveal.

Because epileptic tissue is characterized by increased neuronal excitability and metabolic abnormalities, techniques that allow precise evaluation of these changes could deepen our understanding of the disease and provide new tools for epilepsy surgery. An alternative MRI approach based on metabolite quantification using chemical exchange saturation transfer (CEST) has been suggested to aid in localizing the epileptogenic zone in preliminary studies. However, limited availability of ultra-high-field MRI, low localization precision of the epileptogenic zone, and lack of systematic validation in patients have delayed its clinical use.

This study aims to explore a cohort of patients with temporal lobe epilepsy who are candidates for surgery using CEST MRI. We will quantify glutamate and glucose concentrations using glu-CEST and gluco-CEST, respectively, and correlate the results with the localization of the epileptogenic zone determined by pre-surgical evaluation, and where applicable, SEEG and post-operative outcomes.

03

Conditions studied

  • Epilepsy (Treatment Refractory)

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with drug-resistant temporal lobe epilepsy (mesial or lateral)
  • Requiring a pre-surgical evaluation including long-term video EEG
  • At least 5 of them will be recruited after surface video EEG indicates the need for further exploration by SEEG
  • With or without a radiologically visible lesion

Exclusion criteria

Exclusion Criteria:

  • Absolute or relative to MRI (metallic implants, including intrauterine devices other than the MIRENA® brand, claustrophobia, etc.)
  • Expected inability to remain still for 90 minutes in a 7T MRI
  • Diabetic individuals
  • Individuals under legal protection measures
  • Pregnant or breastfeeding women
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Patients scheduled to undergo a pre-surgical evaluation for drug-resistant epilepsy.

    Other: CEST sequence on a 7-Tesla MRI

Interventions

  • OtherCEST sequence on a 7-Tesla MRI

    CEST sequence on a 7-Tesla MRI

06

What researchers measure

Primary outcomes

  1. Glucose concentration measured by CEST in the the seizure onset zone (SOZ)

    Time frame: Day 0

Secondary outcomes

  1. Glucose concentration measured by CEST in the irritative zone (IZ)

    Time frame: Day 0

  2. Glucose concentration measured by CEST in the propagation zone

    Time frame: Day 0

  3. Glutamate concentration measured by CEST in the seizure onset zone (SOZ)

    Time frame: Day 0

  4. Glutamate concentration measured by CEST in the irritative zone (IZ)

    Time frame: Day 0

  5. Glutamate concentration measured by CEST in the propagation zone

    Time frame: Day 0

07

Study locations

No study locations are listed for this record.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Jan 2030, 36 months later.

Of 339 non-industry interventional studies with no phase under Epilepsy, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 77. This study's planned 36 months is below that.

Counting every sponsor, half of 360 studies reached it within 42 months; a quarter within 19 and three quarters within 77.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 1, 2026: start Mar 2026 → Jan 2027, primary completion Mar 2029 → Jan 2030 and completion Mar 2029 → Jan 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2025
First posted
Jan 5, 2026
StartEst.
Jan 2027was Mar 2026
Primary completionEst.
Jan 2030was Mar 2029
CompletionEst.
Jan 2030was Mar 2029
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Mar 2026→Jan 2027
Oct 1, 2026
Primary completion
Mar 2029→Jan 2030
Oct 1, 2026
Study completion
Mar 2029→Jan 2030
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Start date Mar 2026→Jan 2027
    Primary completion Mar 2029→Jan 2030
    Study completion Mar 2029→Jan 2030
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07316972
Responsible party
Sponsor
First posted
Jan 5, 2026
Start date
Jan 2027 (estimated)
Primary completion
Jan 2030 (estimated)
Completion
Jan 2030 (estimated)
Last update
Oct 1, 2026

Study contacts

Yavchitz
Contact
ayavchitz@for.paris
+33148036454

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion